Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls

Autoimmune Diseases

Volumn 1, Issue 1, 2011, Pages

  Luckman, Steven P ^a   Gilhus, Nils Erik ^a,b   Romi, Fredrik ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

STROMELYSIN;

ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; STROKE;

EID: 84864741818     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.4061/2011/151258     Document Type: Article

References (24)

1. Sternlicht M. D., Werb Z., Kreis T., Vale R., ECM proteinases Guidebook to the Extracellular Matrix and Adhesion Proteins 1999 New York, NY, USA Oxford University Press 503 562
2. Yong V. W., Agrawal S. M., Stirling D. P., Targeting MMPs in acute and chronic neurological conditions Neurotherapeutics 2007 4 4 580 589 (Pubitemid 47499287)
3. VanSaun M., Werle M. J., Matrix metalloproteinase-3 removes agrin from synaptic basal lamina Journal of Neurobiology 2000 43 2 140 149 (Pubitemid 30241212)
4. VanSaun M., Herrera A. A., Werle M. J., Structural alterations at the neuromuscular junctions of matrix metalloproteinase 3 null mutant mice Brain Cell Biology 2003 32 9 1129 1142 (Pubitemid 39004722)
5. Lindstrm J. M., Seybold M. E., Lennon V. A., Whittingham S., Duane D. D., Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value Neurology 1998 51 933 939
6. Evoli A., Batocchi A. P., Minisci C., Di Schino C., Tonali P., Therapeutic options in ocular myasthenia gravis Neuromuscular Disorders 2001 11 2 208 216 (Pubitemid 32201147)
7. Wilcox N., Myasthenia gravis Current Opinion in Immunology 1993 5 910 917
8. Li Z., Forester N., Vincent A., Modulation of acetylcholine receptor function in TE671 (rhabdomyocyosarcoma) cells by non-AchR ligands: possible relevance to seronegative myasthenia gravis Journal of Neuroimmunology 1996 64 2 179 183 (Pubitemid 26094634)
9. Mossman S., Vincent A., Newsom-Davis J., Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity The Lancet 1986 1 8473 116 118 (Pubitemid 16183103)
10. Hoch W., Mcconville J., Helms S., Newsom-Davis J., Melms A., Vincent A., Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies Nature Medicine 2001 7 3 365 368 (Pubitemid 32224355)
11. McConville J., Farrugia M. E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., Vincent A., Detection and characterization of MuSK antibodies in seronegative myasthenia gravis Annals of Neurology 2004 55 4 580 584 (Pubitemid 38391977)
12. Fuhrer C., Sugiyama J. E., Taylor R. G., Hall Z. W., Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle European Molecular Biology Organization Journal 1997 16 16 4951 4960 (Pubitemid 27348404)
13. Borges L. S., Ferns M., Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering Journal of Cell Biology 2001 153 1 1 11 (Pubitemid 34280189)
14. Zucker S., Lysik R. M., Zarrabi M. H., Greenwald R. A., Gruber B., Tickle S. P., Baker T. S., Docherty A. J. P., Elevated plasma stromelysin levels in arthritis Journal of Rheumatology 1994 21 12 2329 2333
15. Kotajima L., Aotsuka S., Fujimani M., Okawa-Takatsuji M., Kinoshita M., Sumiya M., Obata K., Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis Clinical and Experimental Rheumatology 1998 16 4 409 415 (Pubitemid 28370851)
16. Christensen P. B., Jensen T. S., Tsiropoulos I., Sorensen T., Kjaer M., Hojer-Pedersen E., Rasmussen M. J. K., Lehfeldt E., Associated autoimmune diseases in myasthenia gravis. A population-based study Acta Neurologica Scandinavica 1995 91 3 192 195
17. Sthoeger Z., Neiman A., Elbirt D., Zinger H., Magen E., Burstein R., Eitan S., Abarbanel J., Mozes E., High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study American Journal of the Medical Sciences 2006 331 1 4 9 (Pubitemid 43177508)
18. Bir E., Szekanecz Z., Czirjk L., Dank K., Kiss E., Szab N. A., Szucs G., Zeher M., Bodolay E., Szegedi G., Bak G., Association of systemic and thyroid autoimmune diseases Clinical Rheumatology 2006 25 2 240 245 (Pubitemid 43372324)
19. Romi F. R., Gilhus N. E., Luckman S. P., Serum matrix metalloproteinase-3 (MMP-3) levels are elevated in myasthenia gravis Journal of Neuroimmunology 2008 195 1-2 96 99
20. Helgeland G., Petzold A., Luckman S. P., Gilhus N. E., Plant G. T., Romi F. R., Matrix metalloproteinases in Myasthenia Gravis European Neurology 2011 65 1 53 58
21. Lien L. M., Hsieh Y. C., Bai C. H., Chen W. H., Chiu H. C., Hsieh F. I., Shyu K. G., Chiou H. Y., Hsu C. Y., Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan Atherosclerosis 2010 212 2 595 600
22. Kanesaka T., Mori M., Hattori T., Oki T., Kuwabara S., Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry 2006 77 2 185 188 (Pubitemid 43220839)
23. Jones G., Herczeg A., Ruegg M. A., Lichtsteiner M., Krger S., Brenner H. R., Substrate-bound agrin induces expression of acetylcholine receptor-subunit gene in cultured mammalian muscle cells Proceedings of the National Academy of Sciences of the United States of America 1996 93 12 5985 5990
24. Meier T., Masciulli F., Moore C., Schoumacher F., Eppenberger U., Denzer A. J., Jones G., Brenner H. R., Agrin can mediate acetylcholine receptor gene expression by aggregation of muscle-derived neuregulins Journal of Cell Biology 1998 141 3 715 726 (Pubitemid 28217916)